Please login to the form below

Not currently logged in
Email:
Password:

Advodart with tamsulosin reduces AUR risk

Data shows that GSK's Avodart and tamsulosin combination treatment reduces the risk of acute urinary retention

Final results from the four-year GlaxoSmithKline (GSK)-sponsored Combination therapy with Avodart and tamsulosin (CombAT) study show that GSK's Avodart (dutasteride) and tamsulosin combination treatment reduces the risk of acute urinary retention (AUR) or Benign Prostatic Hyperplasia (BPH)-related surgery, as well as reduced the risk of BPH clinical progression more than tamsulosin alone. Combination treatment also delivered superior, sustained symptom improvement from month nine compared to either dutasteride or tamsulosin monotherapy. 

A 66 per cent reduction in the risk of AUR or BPH-related surgery was achieved with combination treatment compared to tamsulosin (p<0.001) and there was a 20 per cent reduction compared to dutasteride (p=0.18). The risk of BPH clinical progression with combination treatment was reduced by 44 per cent, compared to tamsulosin and 31 per cent for those on dutasteride. 

The combination therapy was generally well tolerated, with erectile dysfunction and retrograde ejaculation the most commonly reported drug-related adverse events. The incidence of heart failure was however higher in the combination (0.9 per cent) and tamsulosin (0.6 per cent) than in the dutasteride group (0.2 per cent). There was no difference in overall cardiovascular events across treatment groups. 

Affecting 50 per cent of men over 50 years old, BPH is not life-threatening, but if left untreated, can lead to AUR, a complete obstruction of urinary excretion and BPH-related surgery.

12th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics